{
    "clinical_study": {
        "@rank": "121166", 
        "arm_group": {
            "arm_group_label": "BMS-833923", 
            "arm_group_type": "Experimental", 
            "description": "BMS-833923, by mouth, at the dose and schedule administered while enrolled in CA194002."
        }, 
        "brief_summary": {
            "textblock": "This is an extension study of Protocol CA194002 to allow 2 specific participants with basal\n      cell nevus syndrome in the CA194002 study at Princess Margaret Cancer Centre who are still\n      benefitting from the study drug BMS-833923 to continue receiving the study drug. This study\n      will continue to evaluate the safety and tolerability of BMS-833923 in these participants."
        }, 
        "brief_title": "Study of BMS-833923 in Two Specific Patients With Basal Cell Nevus Syndrome", 
        "completion_date": {
            "#text": "August 2019", 
            "@type": "Anticipated"
        }, 
        "condition": "Basal Cell Nevus Syndrome", 
        "condition_browse": {
            "mesh_term": [
                "Basal Cell Nevus Syndrome", 
                "Nevus", 
                "Nevus, Pigmented"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Signed consent\n\n          -  Two specific study participants enrolled on protocol CA194002 at Princess Margaret\n             Cancer Centre and remain on BMS-833923 at the time of study entry\n\n          -  Women, age 18 years and above\n\n          -  Agree to use methods to prevent pregnancy, not pregnant or breastfeeding\n\n        Exclusion Criteria:\n\n          -  Known symptomatic brain metastasis\n\n          -  A serious uncontrolled medical disorder or active infection, which would impair the\n             ability of the patient to receive protocol therapy\n\n          -  Gastrointestinal disease or surgery that could impact the absorption of study drug\n\n          -  Inability to swallow oral medication\n\n          -  Inability to be venipunctured and/or tolerate venous access\n\n          -  Uncontrolled or significant cardiovascular\n\n          -  Any other medical, psychiatric and/or social reason\n\n          -  Have HIV, HepB, or HepC\n\n          -  Exposure to immunosuppressants and immunotherapy concurrently with study treatment\n             and up to 3 months\n\n          -  Acceptable physical and laboratory test findings\n\n          -  History of allergy to compounds chemically-related"
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "2", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 28, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02100371", 
            "org_study_id": "CA194-103"
        }, 
        "intervention": {
            "arm_group_label": "BMS-833923", 
            "intervention_name": "BMS-833923", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "BMS-833923", 
            "CA194002"
        ], 
        "lastchanged_date": "March 26, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Toronto", 
                    "country": "Canada", 
                    "state": "Ontario", 
                    "zip": "M5G 2M9"
                }, 
                "name": "Princess Margaret Cancer Centre"
            }
        }, 
        "location_countries": {
            "country": "Canada"
        }, 
        "number_of_arms": "1", 
        "official_title": "Extension Protocol of BMS-833923 in Subjects With Basal Cell Nevus Syndrome", 
        "overall_official": {
            "affiliation": "Princess Margaret Cancer Centre", 
            "last_name": "Lillian Siu, M.D.", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": [
                "Canada: Ethics Review Committee", 
                "Canada: Health Canada"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "February 2019", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Frequency of side effects experienced per participant", 
            "safety_issue": "Yes", 
            "time_frame": "From date of first study drug dose taken for this study until participant discontinuation, assessed up to 5 years"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02100371"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "Length of time participants' disease does not worsen", 
            "safety_issue": "No", 
            "time_frame": "From date of first study drug dose taken for this study until the date of first documented progression or date of death from any cause, whichever comes first, accessed up to 5 years"
        }, 
        "source": "University Health Network, Toronto", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "University Health Network, Toronto", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "February 2014", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}